Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Predictable alphabeta T-cell receptor selection toward an HLA-B*3501-restricted human cytomegalovirus epitope.

Brennan RM, Miles JJ, Silins SL, Bell MJ, Burrows JM, Burrows SR.

J Virol. 2007 Jul;81(13):7269-73. Epub 2007 Apr 25.

2.

Identification of novel CTL epitopes of CMV-pp65 presented by a variety of HLA alleles.

Kondo E, Akatsuka Y, Kuzushima K, Tsujimura K, Asakura S, Tajima K, Kagami Y, Kodera Y, Tanimoto M, Morishima Y, Takahashi T.

Blood. 2004 Jan 15;103(2):630-8. Epub 2003 Aug 28.

3.

Cross-recognition of HLA DR4 alloantigen by virus-specific CD8+ T cells: a new paradigm for self-/nonself-recognition.

Rist M, Smith C, Bell MJ, Burrows SR, Khanna R.

Blood. 2009 Sep 10;114(11):2244-53. doi: 10.1182/blood-2009-05-222596. Epub 2009 Jul 17.

4.
5.

Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice.

La Rosa C, Wang Z, Brewer JC, Lacey SF, Villacres MC, Sharan R, Krishnan R, Crooks M, Markel S, Maas R, Diamond DJ.

Blood. 2002 Nov 15;100(10):3681-9. Epub 2002 Jul 12.

6.

Clonotype selection and composition of human CD8 T cells specific for persistent herpes viruses varies with differentiation but is stable over time.

Iancu EM, Corthesy P, Baumgaertner P, Devevre E, Voelter V, Romero P, Speiser DE, Rufer N.

J Immunol. 2009 Jul 1;183(1):319-31. doi: 10.4049/jimmunol.0803647.

7.

Impact of clonal competition for peptide-MHC complexes on the CD8+ T-cell repertoire selection in a persistent viral infection.

Wynn KK, Fulton Z, Cooper L, Silins SL, Gras S, Archbold JK, Tynan FE, Miles JJ, McCluskey J, Burrows SR, Rossjohn J, Khanna R.

Blood. 2008 Apr 15;111(8):4283-92. doi: 10.1182/blood-2007-11-122622. Epub 2008 Feb 12.

9.

Analysis of the human cytomegalovirus pp65-directed T-cell response in healthy HLA-A2-positive individuals.

Schalich J, Vytvytska O, Zauner W, Fischer MB, Buschle M, Aichinger G, Klade CS.

Biol Chem. 2008 May;389(5):551-9.

PMID:
18953722
10.
11.

Structural bases for the affinity-driven selection of a public TCR against a dominant human cytomegalovirus epitope.

Gras S, Saulquin X, Reiser JB, Debeaupuis E, Echasserieau K, Kissenpfennig A, Legoux F, Chouquet A, Le Gorrec M, Machillot P, Neveu B, Thielens N, Malissen B, Bonneville M, Housset D.

J Immunol. 2009 Jul 1;183(1):430-7. doi: 10.4049/jimmunol.0900556.

12.

Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy.

Trivedi D, Williams RY, O'Reilly RJ, Koehne G.

Blood. 2005 Apr 1;105(7):2793-801. Epub 2004 Oct 28.

14.

CD8+ suppressor and cytotoxic T cells recognize the same human leukocyte antigen-A2 restricted cytomegalovirus peptide.

Qin H, Vlad G, Cortesini R, Suciu-Foca N, Manavalan JS.

Hum Immunol. 2008 Nov;69(11):776-80. doi: 10.1016/j.humimm.2008.08.287. Epub 2008 Oct 9.

PMID:
18848854
15.

Preparation and identification of HLA-A*1101 tetramer loading with human cytomegalovirus pp65 antigen peptide.

Li F, Xu L, Zha Q, Chi X, Jia Q, He X.

Cell Mol Immunol. 2007 Apr;4(2):141-6.

16.

Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection.

Diamond DJ, York J, Sun JY, Wright CL, Forman SJ.

Blood. 1997 Sep 1;90(5):1751-67.

17.
18.

Association between the HLA haplotype and the TCR-Vbeta repertoire of anti-hCMV specific memory T-cells in immunocompetent healthy adults.

Rodriguez-Caballero A, Garcia-Montero AC, Almeida J, Balanzategui A, Munoz-Criado S, Orfao A.

Cytometry B Clin Cytom. 2007 Sep;72(5):371-9.

19.

Supplemental Content

Support Center